These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 29741512)
21. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies. Nagle SJ; Garfall AL; Stadtmauer EA Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014 [TBL] [Abstract][Full Text] [Related]
22. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition. Houot R; Schultz LM; Marabelle A; Kohrt H Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ. Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631 [TBL] [Abstract][Full Text] [Related]
29. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer. Hombach AA; Abken H Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616 [No Abstract] [Full Text] [Related]
30. Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges? Davila ML; Brentjens R Hematol Oncol Clin North Am; 2013 Apr; 27(2):341-53. PubMed ID: 23561477 [TBL] [Abstract][Full Text] [Related]
31. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma. Cohen AD Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888 [No Abstract] [Full Text] [Related]
32. Armed T cells with CAR for cancer immunotherapy. Wei YQ Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712 [No Abstract] [Full Text] [Related]
33. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300 [TBL] [Abstract][Full Text] [Related]
34. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. Di S; Li Z Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709 [TBL] [Abstract][Full Text] [Related]
36. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680 [TBL] [Abstract][Full Text] [Related]
37. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525 [TBL] [Abstract][Full Text] [Related]